百奥泰达尔扑拜单抗注射液上市许可申请获得受理

Group 1 - The core point of the article is that Baiotai (688177) has received the acceptance notice from the National Medical Products Administration for its investigational drug BAT4406F, which is intended for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 (AQP4) antibodies [1] - As of the announcement date, BAT4406F is undergoing a Phase II/III registration clinical study targeting minimal change disease/focal segmental glomerulosclerosis (MCD/FSGS), which is the first registered study for this indication in China [1]